Encouraging results support further development of Almirall's

· A phase II multi-dose study shows fast-acting and long-lasting efficacy of LAS100977, Almirall's novel once-daily inhaled beta2 agonist (LABA), for the treatment of bronchoconstriction in asthmatic patients.

The release as fetched from its publisher. almirall.com ↗